- Home
- TGL vs INM Comparison
TGL vs INM Comparison
Compare TGL & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TGL
- INM
- Stock Information
- Founded
- TGL 2020
- INM 1981
- Country
- TGL United States
- INM Canada
- Employees
- TGL N/A
- INM N/A
- Industry
- TGL Retail: Computer Software & Peripheral Equipment
- INM Biotechnology: Pharmaceutical Preparations
- Sector
- TGL Technology
- INM Health Care
- Exchange
- TGL Nasdaq
- INM Nasdaq
- Market Cap
- TGL 3.9M
- INM 3.2M
- IPO Year
- TGL 2022
- INM N/A
- Fundamental
- Price
- TGL $1.06
- INM $3.32
- Analyst Decision
- TGL
- INM
- Analyst Count
- TGL 0
- INM 0
- Target Price
- TGL N/A
- INM N/A
- AVG Volume (30 Days)
- TGL 2.9M
- INM 9.5M
- Earning Date
- TGL 08-25-2025
- INM 05-12-2025
- Dividend Yield
- TGL N/A
- INM N/A
- EPS Growth
- TGL N/A
- INM N/A
- EPS
- TGL N/A
- INM N/A
- Revenue
- TGL $1,468,790.00
- INM $4,920,990.00
- Revenue This Year
- TGL N/A
- INM N/A
- Revenue Next Year
- TGL N/A
- INM N/A
- P/E Ratio
- TGL N/A
- INM N/A
- Revenue Growth
- TGL N/A
- INM N/A
- 52 Week Low
- TGL $1.01
- INM $1.72
- 52 Week High
- TGL $145.00
- INM $15.70
- Technical
- Relative Strength Index (RSI)
- TGL 32.05
- INM 59.24
- Support Level
- TGL $1.02
- INM $2.26
- Resistance Level
- TGL $1.11
- INM $5.50
- Average True Range (ATR)
- TGL 0.10
- INM 0.40
- MACD
- TGL 0.02
- INM 0.11
- Stochastic Oscillator
- TGL 6.44
- INM 37.04
About TGL Treasure Global Inc.
Treasure Global Inc has created an online-to-offline e-commerce platform business model offering consumers and merchants instant rebates and affiliate cashback programs, while providing a seamless e-payment solution with rebates in both e-commerce and physical retailers/merchant settings. Its product is an internet application branded ZCITY app, that targets consumers by providing personalized deals based on consumers' purchase history, location and preferences.
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.